Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879312 | 0.81 | GBA1 (0.79) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL4986451 | 0.81 | GBA1 (0.79) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL27807197 | 0.81 | GBA1 (0.79) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL8844331 | 0.79 | GBA1 (1.00) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL8844329 | 0.79 | GBA1 (1.00) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL9164476 | 0.77 | NLRP3 (0.67) | ALDH1A1TSHRCA12CA9CA1 | |
| SCHEMBL27832629 | 0.76 | GBA1 (0.76) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL25188261 | 0.75 | GBA1 (0.47) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL7862567 | 0.75 | GBA1 (0.74) | GBA1ALDH1A1TSHRCA12CA9 | |
| SCHEMBL29543465 | 0.74 | GBA1 (0.72) | GBA1ALDH1A1TSHRCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | GBA1 1716/4885ALDH1A1 2918/4885TSHR 4278/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | GBA1 1716/4885ALDH1A1 2918/4885TSHR 4278/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | GBA1 1716/4885ALDH1A1 2918/4885TSHR 4278/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | GBA1 1716/4885ALDH1A1 2918/4885TSHR 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.